

Time				01.4.2021	02.04.2021 Holiday	3.4.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM				Clinics Lecture- MEDICINE IM5.1 Describe and discuss the physiologic and biochemical basis of hyperbilirubinemia		MI 1.1: Overview of bacterial infections and Bacterial Taxonomy
9 AM-12 PM				Clinical Posting- SCHEDULE MADE		AETCOM (9am – 11am) Module 2.1: The foundations of communication – 2 Focused small group session
12 PM-1 PM				MI 1.1: Introduction, History of Microbiology		PH 1.1 - (11pm -12pm) Principles of pharmacology and Pharmacotherapeutics
2PM – 4PM				PA 13.1 Describe hematopoiesis and extramedullary hematopoiesis PA13.2Describe the role of anticoagulants in hematology		SDL Pharma 1 Orphan drug, P drug, Essential drugs

Time	05.4.2021	06.4.2021	07.4.2021	8.4.2021	9.4.2021	10.4.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 1.1 Basic Aspects of Forensic Medicine, State Medicine, Legal Medicine and Medical Jurisprudence FM 1.2 History of Forensic Medicine	Patho PA1.1 role of a pathologist in diagnosis & management of disease; lecture	PH 1.4- Describe and evaluate Pharmacokinetics - I	Clinics Lecture- MEDICINE IM5.2 Describe and discuss the aetiology and pathophysiology of liver injury IM5.3 Describe and discuss the pathologic changes in various forms of liver disease	Clinics Lecture SURGERY SU 2.1 Describe pathophysiology of shock & principles of resuscitation including fluid replacement and monitoring SU 2.2 Describe the clinical features of shock and its appropriate treatment	MI 1.1: Identification of Bacteria (Conventional & automated, Molecular)
9 AM-12 PM	Clinical Posting SCHEDULE MADE	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9am – 11am) Module 2.1: The foundations of communication – 2 Focused small group session - 2 hours (11pm -12pm) PH 1.4- Describe and evaluate Pharmacokinetics - II
12 PM-1 PM	PH 1.11- Routes of drug administration	MI 1.1: Morphology of Bacteria	Patho - PA1.2 Enumerate common definitions and terms used in Pathology	MI 1.4: Sterilization and Disinfection	Patho PA1.3 Describe the history and evolution of Pathology	SDL Pathology PA2.2 Cell injury.

2PM – 4PM	FMT PRACTICAL BATCH 1 INTRODUCTION TO PRACTICAL ASPECTS CM Practical batch 2 Introduction of practical aspects CM 7.4 practical batch 2 Define, calculate and interpret morbidity and mortality indicators based on given set of data	Batch -1 (Micro) MI 1.2: Different types of Microscope and Microscopy	Batch -1 (Pharma) PH 2.1- Various dosage forms (oral/local/parenteral;solid/liquid)	PA13.3 Define and classify anemia IM9.1,9.2,9.6 PE 29.1,BI6.11, BI6.12 MI 2.4 Infections causing anemia	Batch -1 (Patho) Departmental orientation	
		Batch 2 – (Patho) Departmental orientation	Batch 2 – (Micro) MI 1.2: Different types of Microscope & Microscopy		Batch 2 – (Pharma) PH 2.1- Various dosage forms (oral/local/parenteral; solid/liquid)	
Time	12.4.2021	13.4.2021	14.4.2021	15.4.2021	16.4.2021	17.4.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM 7.1 : Define Epidemiology and describe and enumerate the principles, concepts and uses CM 7.3: Enumerate, describe and discuss the sources of epidemiological	Patho PA2.1 Causes, mechanisms, types and effects of cell injury and their clinical significance	PH 1.5 - Describe and evaluate Pharmacodynamics - I	Clinics Lecture MEDICINE IM5.4 Describe and discuss the epidemiology, microbiology, immunology and clinical evolution	Clinics Lecture SURGERY SU 1.1 Describe the Basic concepts of homeostasis, enumerate the metabolic changes in injury and their mediators SU 1.2 Describe the factors that affect the metabolic response to injury	MI 1.1: Overview of Viral infections and General Virology

	data			of infective (viral) hepatitis	SU 1.3 Describe the basic concepts of perioperative care	
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM Module 2.1: The foundations of communication – 2, Skills lab session – 1 Hr (11pm -12pm) PH 1.59 - Essential medicines, FDC, OTC drugs, herbal medicines
12 PM-1 PM	PH 1.4 - Describe and evaluate Pharmacokinetics - III	MI 1.1: Bacterial Genetics	Patho PA2.2 Cell injury. - etiology and morphology of cell injury	MI 1.6: Antimicrobials, AMR, AST, Monitoring of AMT, Antimicrobial stewardship	Patho PA2.4 Cell death- types, mechanisms, necrosis, apoptosis, autolysis, PA 2.7 Cellular aging and apoptosis	MI 1.1: Physiology of Bacteria
2PM – 4PM	FMT PRACTICAL BATCH 2 INTRODUCTION TO PRACTICAL ASPECTS CM 7.4 practical batch 1 Introductio to practical aspects Define, calculate and interpret morbidity and mortality indicators based on given set of data	Batch -1 (Micro) MI 1.5: Sterilization and Disinfection (including CSSSD visit)	Batch -1 (Pharma) Prescription writing, DOAP	PA13.4 Enumerate and describe the investigation of anemia IM9.7,9.8,9.9.,9.8,9.10, IM 9.13 PH 1.55 Colony stimulating factors and plasma expanders	Batch -1 (Patho) PA13.5 Perform, Identify and describe the peripheral blood picture in anemia DOAP session	
		Batch 2 Path PA13.5 Peripheral blood picture in anemia DOAP session	Batch 2 – (Micro) MI 1.5: Sterilization and Disinfection (including CSSSD		Batch 2 – (Pharma) Prescription writing, DOAP	

Time	19.4.21	20.4.21	21.4.21	22.4.21	23.4.21	24.4.21
	Monday	Tuesday	Wednesday	Thursday	Friday	
8 AM-9 AM	FM 3.1 IDENTIFICATION - I	Patho PA 2.5; Describe and discuss pathologic calcifications, gangrene	Pharma – PH 5.1 Communicate with the patient with empathy and ethics on all aspects of drug use	Clinics Lecture MEDICINE IM5.5 Describe and discuss the pathophysiology and clinical evolution of alcoholic liver disease	Clinics Lecture SURGERY SU 3.1 Describe the indications and appropriate use of blood and blood products and complications of blood transfusion	AETCOM Module 2.1: The foundations of communication – 2, Skills lab session – 1 Hr Reflections
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Pharma 11-12pm PH 1.64 - Overview of drug development, clinical trial and good clinical practice
12 PM-1 PM	PH 1.5 - Describe and evaluate Pharmacodynamics - II	MI: 1.1: Overview of parasitic infections and General Parasitology	Patho PA2.6; Describe and discuss cellular adaptations: atrophy, hypertrophy, hyperplasia, metaplasia, dysplasia	MI 1.1: Overview of fungal infections and General Mycology	Patho PA3.1; Describe the pathogenesis and pathology of amyloidosis	Sports
2PM – 4PM	FMT PRACTICAL - BATCH 1 DETERMINATION OF RACE CM Practical Batch 2 CM7.6 Enumerate and evaluate the need of screening tests	Batch -1 (Micro) MI 1.1: Culture Media and Culture Methods Batch 2 – (Patho) PA2.8; Cell injury features in gross and microscopic specimens DOAP session	Batch -1 (Pharma) PH 3.1 Prescription writing, PERFORM Batch 2 – (Micro) MI 1.1: Culture Media and Culture Methods	PA14.1 Describe iron metabolism PE 13.1 PH 1.35 Drugs used in anemia	Batch -1 (Patho) PA2.8; Identify and describe cell injury features in gross and microscopic specimens DOAP session Batch 2 – (Pharma) PH 3.1 Prescription writing, PERFORM	

Time	Monday 26.4.21	Tuesday 27.4.21	Wednesday 28.4.21	Thursday 29.4.21	Friday 30.4.21	Saturday 1.5.21
8 AM-9 AM	CM 7.5: Enumerate, define, describe and discuss epidemiological study designs	Patho PA4.1 General features of acute and chronic inflammation	Pharma – PH 1.2 Evidence based medicine (SGD 1)	Clinics Lecture MEDICINE IM8.1 Describe and discuss the epidemiology, aetiology and the prevalence of primary and secondary hypertension IM8.5 Describe and discuss the differences between primary and secondary hypertension IM8.7 Describe and discuss the clinical manifestations of the various aetiologies of secondary causes of hypertension	Clinics Lecture SURGERY SU 5.1 Describe normal wound healing and factors affecting healing	MI 1.8: Components of Immune System-Organs, cells and products
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting		AETCOM Module 2.1: The foundations of communication – 2 Discussion and closure – 1 hour
						(11pm -12pm) Pharma – PH 1.6 & 1.7 ADR and Pharmacovigilance (SGD 2)

12 PM-1 PM	Pharma – PH 1.9 Nomenclature of drugs – branded/generic (SGD 3)	MI 1.3: Epidemiology of infectious diseases	Patho PA4.2 Mediators of acute inflammation	MI 1.7: Immunity (Innate and Acquired)- Immunological mechanisms in health	Patho PA4.2 Mediators of acute inflammation Contd.	SDL Pharma 2 Pharmacogenetics and pharmacogenomics
2PM – 4PM	FMT PRACTICAL - BATCH - 2 DETERMINATION OF RACE CM batch 1: CM7.6 Enumerate and evaluate the need of screening tests	Batch -1 (Micro) MI 1.2: Gram staining -1 MI 1.1: Morphology of bacteria, growth curve	Batch -1 (Pharma) PH 2.3 Setting up of an intravenous drip	PA14.2 Describe the etiology, investigations and differential diagnosis of microcytic hypochromic anemia PE 29.2 PE 13.2 PE 13.3 PE 13.4 PE 13.5 IM 9.9	Batch -1 (Patho)PA4.4; Acute inflammation in specimens DOAP session	
		Batch 2 – (Patho) PA4.4; Acute inflammation gross and microscopic specimens DOAP session	Batch 2 – (Micro) MI 1.2: MI 1.1:		Batch -2 (Pharma) PH 2.3 Setting up of an intravenous drip	

Time	3.5.2021 Monday	4.5.2021 Tuesday	5.5.2021 Wednesday	6.5.2021 Thursday	7.5.2021 Friday	8.5.2021 Saturday
8 AM-9 AM	FM 3.1 IDENTIFICATION - I (CONT)	Patho PA4.2 Mediators of acute inflammation SGD	Pharma PH 1.13 Describe the MOA,types, dosage,S/E of drugs of Adrenergic System - I	Clinics Lecture OBGY OG2.1 Describe and discuss the development and anatomy of the female reproductive tract, relationship to other pelvic organs, applied anatomy as related to Obstetrics and Gynaecology. (part 1)	Clinics Lecture SURGERY SU 5.2 Elicit,document and present a history in a patient with wounds SU 5.3 Differentiate the various types of wound, plan and observe management of wounds SU 5.4 Discuss the medicolegal aspects of wound	MI 1.8: Antigen-Antibody Reaction 1

9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.2 The foundations of bioethics large group session - 2 hours
						Pharma (11pm -12pm) PH 1.13 Describe the MOA,types, dosage,S/E of drugs of Adrenergic System - II
12 PM-1 PM	Pharma PH 1.8 -Drug Interactions (SGD 4)	MI 1.8: Antigen	Patho PA4.3 Chronic inflammation	MI 1.8: Antibody	Patho PA5.1 Repair and regeneration ,wound healing and its types SU 5.1	SDL Pathology PA 6.4 Normal haemostasis etiopathogenesis and consequences of thrombosis SDL
2PM – 4PM	FMT PRACTICAL - BATCH 1 FM 14.9 EXAMINATION OF SKULL & MANDIBLE Batch 2: CM 7.7 Describe and demonstrate the steps in the Investigation of an epidemic of communicable disease and describe the principles of control measures	Batch -1 (Micro) MI 8.9 & MI 8.10: Specimen collection and transport	Batch -1 (Pharma) PH 2.2 - ORS preparation	PA14.3 Identify and describe the peripheral smear in microcytic anemia DOAP session IM9.11, MI 2.6, MI 2.5 Identify the causative agents of Malaria and Leishmaniasis from smear	Batch -1 (Patho)PA4.4; Acute inflammation in specimens DOAP session	
		Batch 2 – (Patho)PA4.4; Acute inflammation in specimens DOAP session Contd.	Batch 2 – (Micro) MI 8.9 & MI 8.10: Specimen collection and transport		Batch 2 – (Pharma) PH 2.2 - ORS preparation	
Time	10.5.2021	11.5.2021	12.5.2021	13.5.2021	14.5.2019 Friday Holiday	15.5.2021 Saturday
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM 7.8: Describe the principles of association, causation and biases in	Patho PA 6.1 Edema, types, pathogenesis and clinical correlations SGD	Pharma PH 1.13 Drugs used in glaucoma Adrenergic System - IV	Clinics Lecture OBYG OG2.1 Describe and discuss the development and anatomy of the		MI 1.8: Immune Responses: Cell-mediated and Antibody-mediated

	epidemiological studies			female reproductive tract, relationship to other pelvic organs, applied anatomy as related to Obstetrics and Gynaecology. (part 2)		
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting		AETCOM (9-11) Module 2.3: Health care as a right Participatory student seminar - 2 hrs
						Pharma (11pm -12pm) PH 1.14 Describe the MOA,types, dosage,S/E of drugs of Cholinergic System - I
12 PM-1 PM	Pharma PH 1.13 Describe the MOA,types, dosage,S/E of drugs of Adrenergic System - III	MI 1.8: Antigen-Antibody Reaction 2	Patho PA 6.3 Shock, its pathogenesis and its stages SGD SU2.1	MI 1.8: Complement		MI 1.1: Plague
2PM – 4PM	FMT PRACTICAL - BATCH 2 FM 14.9 EXAMINATION OF SKULL & MANDIBLE Batch 1: CM 7.7 Describe and demonstrate the steps in the Investigation of an epidemic of communicable disease and describe the principles of control measures	Batch -1 (Micro) MI 1.1 & MI 1.2: Laboratory diagnosis of viral & parasitic infections. Stool microscopy-1, PBS Batch 2 – (Patho)PA 6.2Hyperemia, congestion, hemorrhage SGD	Batch -1 (Pharma) PH 2.4 Dosage Calculation Batch 2 – (Micro) MI 1.1 & MI 1.2: Laboratory diagnosis of viral & parasitic infections. Stool microscopy-1, PBS	PA16.1 Define and classify hemolytic anemia PA 10.1 Pathogenesis and pathology of malaria SGD MI 2.5: Malaria 1		
Time	17.5.2021	18.5.2021	19.5.2021	20.5.2021	21.5.2021	22.5.2021

	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.2 IDENTIFICATION - II	Patho PA6.5 Embolicism ,causes and common types SGD	Pharma PH 1.1 Describe the MOA,types, dosage,S/E of drugs of Cholinergic System - III	Clinics Lecture OBGY OG3.1 Describe the physiology of ovulation, menstruation, fertilization, implantation and gametogenesis.(part 1)	Clinics Lecture SURGERY SU 4.1 Elicit document and present history in a case of Burns and perform physical examination. Describe Pathophysiology of Burns.	MI 1.1: Blood stream infections, sepsis, septic shock, CRBSI
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.4: Working in a health care team “Tag along” session in hospital- 2 hours Pharma (11pm -12pm) PH 1.31 Drugs for dyslipidemia
12 PM-1 PM	Pharma PH 1.1 Describe the MOA,types, dosage,S/E of drugs of Cholinergic System - II	MI 1.8: Immune Responses: Cell-mediated and Antibody-mediated 2	Patho PA6.6 Ischaemia/infarction its types, etiology, morphologic changes SGD	MI 1.9: Immunoprophylaxis & Immunohematology	Patho PA7.1 Neoplasia. Definition,characteristics Difference benign & malignant neoplasms IM 13.3, 13.4	Sports
2PM – 4PM	FMT PRACTICAL - BATCH 1 FM 14.9 EXAMINATION OF UPPER LIMB BONES Batch 2: CM 3.8: Describe the mode of action, application cycle of commonly used insecticides and rodenticides	MI 1.1, 1.2: Laboratory diagnosis of fungal infections Normal Microbial Flora Batch 2 – (Patho)PA 6.7Infarction in specimen DOAP session	Batch -1 (Pharma) PH4.2 Computer Assisted Learning (CAL) MI 1.1, 1.2: Laboratory diagnosis of fungal infections Normal Microbial Flora	PA16.2 Describe the pathogenesis and clinical features and hematologic indices of hemolytic anemia MI 2.5& MI 1.1: Malaria 2 & Babesiosis	Batch -1 (Patho)PA 6.2Hyperemia, congestion, hemorrhage SGD Batch 2 – (Pharma) PH4.2 Computer Assisted Learning (CAL)	

	(integration with pharma)					
--	---------------------------	--	--	--	--	--

Time	24.5.2021	25.5.2021	26.5.2021 HOLIDAY	27.5.2021	28.5.2021	29.5.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	<p>CM 3.6: Describe the role of vectors in the causation of diseases. Also discuss National Vector Borne disease Control Program (integration micro)</p> <p>CM 3.7: Identify and describe the identifying features and life cycles of vectors of Public Health importance and their control measures (integration micro)</p>	PathoPA 7.2 Molecular basis of cancer IM 13.2		Clinics Lecture OBGY OG3.1 Describe the physiology of ovulation, menstruation, fertilization, implantation and gametogenesis. (part 2)	Clinics Lecture SURGERY SU 4.2 Describe Clinical features. Diagnose type and extent of burns and plan appropriate treatment. SU 4.3 Discuss the medicolegal aspects in burn injuries	MI 1.1: Rickettsial infections
9 AM-12 PM	Clinical Posting	Clinical Posting		Clinical Posting	Clinical Posting	<p>AETCOM (9-11) Module 2.4: Working in a health care team “Tag along” session in hospital- 2 hours</p> <p>Pharma (11pm -12pm) PH 1.16 Describe the MOA,types, dosage,S/E of Autacoids</p>

						(SGD 6)
12 PM-1 PM	Pharma PH 1.16 Describe the MOA,types, dosage,S/E of Autacoids (SGD 5)	MI 2.1, 2.2: Infections of CVS		MI 3.3: Enteric (typhoid) fever	Patho PA 7.4 effects of tumor on the host, paraneoplastic syndrome PA 7.5 Describe immunology and the immune response to cancer,BI10.2	SDL Pharmacology 3 Anti-diuretics
2PM – 4PM	FMT PRACTICAL - BATCH 2 FM 14.9 EXAMINATION OF UPPER LIMB BONES Batch 1 CM 3.8: Describe the mode of action, application cycle of commonly used insecticides and rodenticides (integration with pharma)	MI 1.8, 8.15: Antigen-Antibody Reaction Batch 2 – (Patho)PA 7.3 carcinogens, process of carcinogenesis SGD IM 13.1,,IM 13.15, MI8.3,BI10.1, BI7.7		PA 16.3 Pathogenesis, features, hematologic indices and peripheral blood picture of sickle cell anemia and thalassemia PE 29.4, BI5.2 PH 1.47,BI5.2 Malarial drugs	Batch -1 (Patho)PA 6.7 Infarction in specimen DOAP session Batch 2 – (Pharma) PH 2.4 - Dosage Calculation	

Time	31.5.2021	1.6.2021	2.6.2021	3.6.2021	4.6.2021	5.6.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday

8 AM-9 AM	FM 3.2 IDENTIFICATION - II (CONT)	Patho PA 8.1 Cytology PA 8.2 Exfoliative cytology SGD	Pharma PH 1.24 -Evaluate the indications, C/I, S/E of diuretics Renal	Clinics Lecture MEDICINE IM8.2 Describe and discuss the pathophysiology of hypertension IM8.3 Describe and discuss the genetic basis of hypertension IM8.4 Define and classify hypertension	Clinics Lecture OBYG OG4.1 Describe and discuss the basic embryology of fetus, factors influencing fetal growth and development , anatomy and physiology of placenta, and teratogenesis (part1)	MI 1.1: Dengue, chikungunya, and Zikavirus
9 AM-12 PM		Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.4: Working in a health care team- SGD - 2 hrs
						Pharma (11pm -12pm) PH 1.26 Describe the MOA, types, dosage, S/E of RAAS
12 PM-1 PM	Pharma PH 1.24 Renal - describe the mech of diuretics	MI 2.7: HIV	Patho PA 9.1 Principles and mechanisms involved in immunity SGD BI10.3	MI 2.7: HIV 2	Patho PA 9.2 Describe the mechanism of hypersensitivity reactions SGD	SDL Pathology Patho PA 9.5 Autoimmune disorders-SLE DR 16.1 bedside discussion
2PM – 4PM	FMT PRACTICAL - BATCH 1 FM 14.9 EXAMINATION OF PELVIC BONE & SACRUM	MI 3.4, 8.15: Enteric (typhoid) fever, Brucellosis, Leptos pirosis MI 1.2: Gram staining - 2	Batch -1 (Pharma) PH 4.2 Computer Assisted Learning (CAL)	PA16.4 Pathogenesis, hematologic indices and peripheral blood picture of Acquired hemolytic anemia	Batch -1 (Patho) PA 7.3 carcinogens, process of carcinogenesis SG D , IM 13.1, IM 13.15, MI 8.2, BI 10.1, BI 7.7	
	Batch 2: CM 5.6 Enumerate and discuss the National Nutrition Policy, important national nutritional Programs including	Batch 2 – (Patho) PA 8.3 diagnostic cytology, staining , interpretation DOAP	MI 1.8, 8.15: Antigen- Antibody Reaction	PH 1.47	Batch 2 – (Pharma) PH 4.2 Computer Assisted Learning (CAL)	

the Integrated Child Development Services Scheme (ICDS) etc						
---	--	--	--	--	--	--

Time	7.6.2021	8.6.2021	9.6.2021	10.6.2021	11.6.2021	12.6.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM 5.1 Describe the common sources of various nutrients and special nutritional requirements according to age, sex, activity, physiological conditions (integration with general medicine/paed)	PathoPA 9.3 HLA system , immune principles in transplant,transplant rejection SGD	Pharma PH 1.27 - Describe the MOA,types, dosage,S/E of drugs for Hypertension - II	Clinics Lecture MEDICINE IM8.8 Describe, discuss and identify target organ damage due to hypertension	Clinics Lecture OBGY OG4.1 Describe and discuss the basic embryology of fetus, factors influencing fetal growth and development, anatomy and physiology of placenta, and teratogenesis(part2)	MI 2.5: Lymphatic filariasis
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.5: Bioethics continued – patient autonomy and decision making Introduction and group formation - 1 hour Case introduction - 1 hour
						Pharma (11pm -12pm) PH 1.55 Describe the MOA,types, dosage,S/E of Immunomodulators
12 PM-1 PM	Pharma PH 1.27 - Describe the MOA,types, dosage,S/E of drugs for Hypertension	MI 1.1: Other viral hemorrhagic fever- Kyasanuar forest disease, Ebola and Marburg virus, Hantaviruses	Patho PA 9.4 Define autoimmunity. Enumerate autoimmune disorders IM 7.1, IM 7.2, IM 7.16	MI 2.5: Leishmaniasis	PathoPA 9.6 Define and describe the pathogenesis and pathology of HIV and AIDS IM 6.5, IM 6.6, IM 6.10, IM 6.19, IM8.2,MI 2.7	SDL Microbiology MI 1.1: Trypanosomiasis and Schistosomiasis

2PM – 4PM	FMT PRACTICAL - BATCH 2 FM 14.9 EXAMINATION OF PELVIC BONE & SACRUM Batch 1: CM 5.6 Enumerate and discuss the National Nutrition Policy, important national nutritional Programs including the Integrated Child Development Services Scheme (ICDS) etc	MI 1.2: Acid fast staining 1	Batch -1 (Pharma) PH 4.1 Drug administration in Mannequin	PA16.5 Describe the peripheral blood picture in different hemolytic anaemias	Batch -1 (Patho)PA 8.3Obderve diagnostic cytology and its staining DOAP session	
		Batch 2 – (Patho) PA 10.2pathogenesis and pathology of Cysticercosis SGD	MI 3.4, 8.15: Enteric fever,Brucellosis,Leptospirosis MI 1.2: Gram staining -2		Batch 2 – (Pharma) PH 4.1 Drug administration in Mannequin	

Time	14.6.2021	15.6.2021	16.6.2021	17.6.2021	18.6.2021	19.6.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.3 MECHANICAL INJURIES & WOUNDS -1	PathoPA 9.7 Pathogenesis of other common autoimmune diseases	Pharma PH 1.16 Describe MOA,types,dosage,S/E of drugs for Rheumatoid Arthritis	Clinics Lecture MEDICINE IM9.1 Define, describe and classify anemia based on red blood cell size and reticulocyte count	Clinics Lecture OBY OG5.1 Describe, discuss and identify pre-existing medical disorders and discuss their management; discuss evidence-based intrapartum care	MI 8.5,8.6: Needle stick injury
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making, SDL- 2 hrs Pharma (11pm -12pm) PH 1.16 - Describe MOA,types,dosage, S/E of drugs for gout

12 PM-1 PM	Pharma PH 1.55 Describe MOA,types,dosage, S/E of Immunomodulators (SGD 7)	MI 1.1: Systemic mycosis and Candidiasis	Patho PA 10.4 pathogenesis and pathology of common bacterial, viral, protozoal, helminthic diseases SGD	MI 8.5,8.6, 8.7: Hospital acquired infection	PA 10.4 pathogenesis and pathology of common bacterial, viral, protozoal, helminthic diseases SGD	Sports
2PM – 4PM	FMT PRACTICAL - BATCH 1 & 2 REVISION CLASS CM Batch 1 & 2 CM5.7 Describe food hygiene CM 5.8 Describe and discuss the importance and methods of food fortification and effects of additives and adulteration	MI 1.2: Acid fast staining 2	Batch -1 (Pharma) PH 4.1 Drug administration in Mannequin	PE24.1, 24.2 & 25.1 diarrheal dehydration, Malabsorption MI 3.1: infective agents causing Diarrheal diseases	Batch -1 PA 10.2 pathogenesis and pathology of Cysticercosis SGD Batch 2 – (Pharma) PH 4.1 Drug administration in Mannequin	
		Batch 2 – (Patho) PA10.3 pathogenesis and pathology of leprosySGD	MI 1.2: Acid fast staining 1			

Time	21.6.2021	22.6.2021	23.6.2021	24.6.2021	25.6.2021	26.6.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM						
9 AM-12 PM						

	Internal Assessment	Internal Assessment
12 PM-1 PM		
2PM – 4PM		

Time	28.6.2021	29.6.2021	30.6.2021	1.7.2021	2.7.2021	3.7.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	Internal Assessment					Internal Assessment
9 AM-12 PM						

12 PM-1 PM	
2PM – 4PM	

Time	5.7.2021	6.7.2021	7.7.2021	8.7.2021	9.7.2021	10.7.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM CM8.1 Describe and discuss the epidemiological and control measures including the use of essential laboratory tests at the primary care level for	PA 11.1 pathogenesis of common cytogenetic abnormalities and mutations in childhood SGD	Pharma PH 1.31 Drugs used in AMI and fibrinolytics	Clinics Lecture MEDICINE IM9.2 Describe and discuss the morphological characteristics, aetiology and prevalence of each of the causes of anemia IM9.7	Clinics Lecture SURGERY SU 6.1 Define and describe the aetiology and pathogenesis of surgical infections SU 6.2 Enumerate Prophylactic and therapeutic antibiotics. Plan appropriate management	MI 3.1: Intestinal amoebiasis Balantidiasis

	communicable diseases (Infectious disease epidemiology)			Describe and discuss the meaning and utility of various components of the hemogram		
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.5: Bioethics continued – Case studies on patient autonomy and decision making, ANCHORING LECTURE AND CASE RESOLUTION- 1+1 hrs
						Pharma (11pm -12pm) PH 1.25,1.31 Antiplatelet drugs
12 PM-1 PM	Pharma PH 1.28 Drugs used in Angina	MI 3.1: Normal commensals Gastrointestinal infective syndromes	PA 11.3 pathogenesis of common storage disorders in infancy and childhood SGD	MI 3.1: Cholera and halophilic Vibrio infections	PA 11.2 pathology of tumor and tumour like conditions in infancy and childhood SGD	SDL Pharma 4 PH 1.27 Management of hypertension in pregnancy
2PM – 4PM	FMT PRACTICAL - BATCH 1 FM 14.9 EXAMINATION OF LOWER LIMB BONES Batch 2: Medical entomology CM 3.7:Identify and describe the identifying features and life cycles of vectors of Public Health importance and their control measures	Batch -1 (Micro) MI 3.1: Giardiasis Intestinal coccidian parasites and microsporidia infections MI 1.2: Stool microscopy-2	Batch -1 (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case I (DOAP)	PA25.1Describe bilirubin metabolism, enumerate the etiology and pathogenesis of jaundice, distinguish between direct and indirect hyperbilirubinemia IM 5.1, IM 5.2,IM 5.3	Batch -1 (Patho) PA10.3pathogenesis and pathology of leprosy SGD	
		Batch 2 – (Patho) PA 15.1 metabolism of Vitamin B12, etiology and pathogenesis of B12 deficiency SGD	Batch 2 – (Micro) MI 3.1: Giardiasis Intestinal coccidian parasites and microsporidia infections MI 1.2: Stool microscopy-2		Batch 2 – (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case I (DOAP)	

--	--	--	--	--	--	--

Time	12.7.2021	13.7.2021	14.7.2021	15.7.2021	16.7.2021	17.7.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.3 MECHANICAL INJURIES & WOUNDS - II	Patho PA 12.1 pathogenesis of disorders caused by air pollution, tobacco and alcohol SDL	Pharma PH 1.31 Drugs used in AMI	Clinics Lecture MEDICINE IM9.8 Describe and discuss the various tests for iron deficiency IM9.14 Describe the national programs for anemia prevention	Clinics Lecture SURGERY SU 7.1 Describe the Planning and conduct of Surgical audit SU 7.2 Describe the principles and steps of clinical research in General Surgery	MI 3.1: Intestinal cestode infections - Diphyllbothrium latum ,Taenia, Hymenolepis Intestinal trematodes infections
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.6: Bioethics continued: Case studies on autonomy and decision making Introduction of case-1hr SDL-1Hr
						Pharma (11pm -12pm)

						PH 1.29 Describe the MOA, types and doses of drugs in CHF
12 PM-1 PM	Pharma PH 1.31 Anti coagulants	MI 3.5: Food poisoning- Bacillus cereus , Clostridium botulinum , mycotoxins Antibiotic associated diarrhea	Patho PA 12.3 pathogenesis of obesity and its consequences SGD IM14.2,,14.3,14.4,14.5 PE11.1, PE 11.2, BI8.1, BI8.4	MI 3.1: Intestinal nematodes- Ascaris, hookworm, Trichuris, Enterobius and Strongyloides	PA 12.2 pathogenesis of protein calorie malnutrition and starvation SGD BI8.2	SDLPathology PA25.2 Describe the pathophysiology and pathologic changes seen in hepatic failure and their clinical manifestations, complications and consequences
2PM – 4PM	FMT PRACTICAL - BATCH 2 FM 14.9 EXAMINATION OF LOWER LIMB BONES Batch 1 Medical entomology CM 3.7:Identify and describe the identifying features and life cycles of vectors of Public Health importance and their control measures	Batch -1 (Micro) MI 3.1: Shigellosis Nontyphoidal salmonellosis Diarrheogenic E.coli MI 1.2: Gram staining-3	Batch -1 (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case II (PERFORM)	PA25.3 Describe the etiology and pathogenesis of viral and toxic hepatitis: distinguish the causes of hepatitis based on the clinical and laboratory features. Describe the pathology, complications and consequences of hepatitis PE 26.1, PE 26.2, PE 26.9, IM 5.4, IM 5.7, MI 3.7, MI 3.8 PH 1.16, 1.44 Drugs causing hepatitis	Batch -1 (Patho) PA 15.1 metabolism of Vitamin B12, etiology and pathogenesis of B12 deficiency PE 29.3SGD	
		Batch 2 – (Patho) PA 15.3 peripheral blood picture of macrocytic anemia DOAP	Batch 2 – (Micro) MI 3.1: Shigellosis Nontyphoidal salmonellosis Diarrheogenic E.coli MI 1.2: Gram staining-3	Batch 2 – (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case II (PERFORM)		

Time	19.7.2021	20.7.2021	21.7.2021 Holiday	22.7.2021	23.7.2021	24.7.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM CM8.1 Describe and discuss the epidemiological and control measures including the use of essential laboratory tests at the primary care level for communicable diseases Infectious disease epidemiology (part 2)	PA 15.2 Describe lab investigations of macrocytic anemia PA15.4 megaloblastic and non-megaloblastic macrocytic anemia SGD	HOLIDAY	Clinics Lecture MEDICINE IM9.11 Describe the indications and interpret the results of a bone marrow aspirations and biopsy	Clinics Lecture SURGERY SU 8.1 Describe the principles of Ethics as it pertains to General Surgery SU 8.2 Demonstrate professionalism and empathy to the patient undergoing General Surgery SU 8.3 Discuss medicolegal issues in surgical practice	MI 3.7: Agents of Viral Hepatitis 2
9 AM-12 PM	Clinical Posting	Clinical Posting		Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.6: Bioethics continued: Case studies on autonomy and decision making contd. SDL-1Hr Anchoring Lecture-1hr
12 PM-1 PM	Pharma PH 1.29 S/E indications and C/I of drugs in CHF	MI 1.1: Echinococcosis Other parasitic infections of liver		MI 3.7: Agents of Viral Hepatitis 1	PA17.1 pathogenesis and findings in aplastic anemia SGD	Pharma (11pm -12pm) PH 1.30 Describe the MOA, types,S/E of antiarrhythmic drugs
						SDL Micro MI 3.1: Viral gastroenteritis

2PM – 4PM	FMT PRACTICAL - BATCH 1 FM 14.9 EXAMINATION OF BUNDLE OF BONES CM practical batch 2 Medical etymology part 2 CM 3.7: Identify and describe the identifying features and life cycles of vectors of Public Health importance and their control measures	Batch -1 (Micro) MI 3.6 MI 3.1: Helicobacter infection, Campylobacter, Yersiniosis MI 1.2: Stool microscopy-3		PA25.4 Describe the pathophysiology, pathology and progression of alcoholic liver disease including cirrhosis PE 26.3, IM 5.5 PH 1.21 Describe effects acute and chronic ethanol intake with management	Batch -1 (Patho) PA 15.3 peripheral blood picture of macrocytic anemia DOAP	
		Batch 2 – (Patho) PA 17.2 Enumerate the indications and describe the findings in bone marrow aspiration and biopsy DOAP		Batch 2 – (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case VII (DOAP)		

Time	26.7.2021	27.7.2021	28.7.2021	29.7.2021	30.7.2021	31.7.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.3 MECHANICAL INJURIES & WOUNDS - III	PA 17.2 Enumerate the indications and describe the findings in bone marrow aspiration and biopsy SGD IM 9.12	Pharma PH 1.32 S/E and Contraindications of drugs of COPD and BA	Clinics Lecture MEDICINE IM9.12 Describe, develop a diagnostic plan to determine the aetiology of anemia IM9.21 Determine the need for specialist consultation	Clinics Lecture SURGERY SU 9.1 Choose appropriate biochemical, microbiological, pathological, imaging investigations and interpret the investigative data in a surgical patient	MI 4.1: Gas gangrene Tetanus (Clostridium tetani) Infections due to non-spring anaerobes
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.6: Bioethics continued: Case studies on

						autonomy and decision making contd. CLOSURE-1Hr
						Pharma (11pm -12pm) PH 1.17 Describe the MOA types and S/E of Local Anaesthetics
12 PM-1 PM	Pharma PH 1.32 Drugs used in COPD and Bronchial Asthma	MI 4.1, 4.2, 4.3: Infective syndromes of skin, soft tissue, musculoskeletal systems	Patho PA 18.1 causes of leucocytosis leucopenia lymphocytosis and leukemoid reactions SGD	MI 4.3: Staphylococcal infections	Patho PA 18.1 causes of leucocytosis leucopenia lymphocytosis and leukemoid reactions contd. SGD	Sports
2PM – 4PM	FMT PRACTICAL - BATCH 2 FM 14.9 EXAMINATION OF BUNDLE OF BONES CM practical Batch 1 Medical entomology part 2 CM 3.7: Identify and describe the identifying features and life cycles of vectors of Public Health importance and their control measures	Batch -1 (Micro) MI 4.3: Leprosy MI 1.2: Gram staining-4	Batch -1 (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case III (PERFORM)	PA25.5 Describe the etiology, pathogenesis and complications of portal hypertension PE26.4, IM 5.6	Batch -1 PA 17.2 Enumerate the indications and describe the findings in bone marrow aspiration and biopsy DOAP	
		Batch 2 – (Patho) PA 16.6 peripheral blood smear to identify hemolytic anaemia from it DOAP	Batch 2 – (Micro) MI 3.6, MI 3.1: Helicobacter infection, Campylobacter, Yersiniosis MI 1.2: Stool microscopy-3		Batch 2 – (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case III (PERFORM)	

Time	2.8.2021	3.8.2021	4.8.2021	5.8.2021	6.8.2021	7.8.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday

8 AM-9 AM	CM CM8.1 Describe and discuss the epidemiological and control measures including the use of essential laboratory tests at the primary care level for communicable diseases (Malaria)	Patho PA 18.2 pathogenesis classification, features, hematologic features of acute leukemia PE 29.8 SGD	Pharma PH 1.18 doses S/E and C/I of General Anaesthetics	Clinics Lecture OBGY OG5.2 Determine maternal high risk factors and verify immunization status	Clinics Lecture SURGERY SU 9.2 Biological basis of early detection of cancer and multidisciplinary approach in management of cancer	MI 4.3 Viral exanthems 2
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.7: Bioethics continued: Case studies on autonomy and decision making INTRODUCTION-1HR
						Pharma (11pm -12pm) PH 1.19 Sedatives
12 PM-1 PM	Pharma PH 1.18 Describe the MOA types and indications of General Anaesthetics	MI 4.1 MI 4.3, 8.15 Infection due to non-fermenters Actinomycetes and Nocardia	Patho PA 18.2 pathogenesis classification, features, hematologic features of acute leukemia Contd. SGD	MI 4.3 Viral exanthems 1	Patho PA 18.2 pathogenesis classification, features, hematologic features of chronic leukemia Contd. SGD	SDL Pharma 5 PH 1.22 Evaluate drugs of abuse

2PM – 4PM	FMT PRACTICAL - BATCH 1 FM 14.9 REVISION CLASS FOR BONES BATCH 2 Food items(cereals ,pulses,veg, oil nuts) CM 5.1: Describe the common sources of various nutrients and special nutritional requirements according to age, sex, activity, physiological conditions	Batch -1 (Micro) MI 4.3, 8.15: Anthrax, Leprosy, Pseudomonas , Melioidosis, Actinomycetes, Nocardia MI 1.2: Gram staining-5	Batch -1 (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case IV (DOAP)	PA25.6 Interpret liver function and viral hepatitis serology panel. Distinguish obstructive from non-obstructive jaundice based on clinical features and liver function tests IM 5.12, IM 5.14	Batch -1 (Patho) PA 16.6 peripheral blood smear to identify hemolytic anaemia from it DOAP	
		Batch 2 – (Patho) PA 19.1 causes and differentiating features of lymphadenopathy SGD	Batch 2 – (Micro) MI 4.3: Leprosy MI 1.2: Gram staining-4	PH 1.48 Antiviral drugs	Batch 2 – (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case IV (DOAP)	

Time	9.8.2021	10.8.2021	11.8.2021	12.8.2021	13.8.2021	14.8.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.3 MECHANICAL INJURIES & WOUNDS - IV	Patho PA 19.2 pathogenesis and pathology of tuberculous lymphadenitis SGD	Pharma PH 1.19 Parkinsonism related drugs	Clinics Lecture OBGY OG6.1 Describe, discuss and demonstrate the clinical features of pregnancy, derive and discuss its differential diagnosis, elaborate the principles underlying and	Clinics Lecture SURGERY SU 10.1 Describe the principles of perioperative management of common surgical procedures	MI 5.1: Infective syndromes of CNS

				interpret pregnancy tests.		
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	<p>AETCOM (9-11) Module 2.7: Bioethics continued: Case studies on autonomy and decision making SDL-2HRS</p> <p>Pharma (11pm -12pm) PH 1.19 Parkinsonism related drugs</p>
12 PM-1 PM	Pharma PH 1.19 Hypnotics	MI 4.3 Tissue nematode infections of skin and soft-tissue	Patho PA 19.4pathogenesis, pathology and the differentiating features of Hodgkin's and non-Hodgkin's lymphoma PE 29.7, IM 4.5 SGD	MI 5.1 Superficial Subcutaneous fungal infections, Candidiasis P marneffeii	Patho PA 19.6 Enumerate and differentiate the causes of splenomegaly SGD	SDL Pathology PA32.1 Enumerate, classify and describe the etiology, pathogenesis, pathology and iodine dependency of thyroid swellings
2PM – 4PM	FMT PRACTICAL - BATCH 2 FM 14.9 REVISION CLASS FOR BONES CM Batch 1 Food items part (cereals, pulse,veg,oil) CM 5.1Describe the common sources of	Batch -1 (Micro) MI 4.1, 4.3, 8.15: Staphylococcal, Streptococcal and Anaerobic infections MI 4.3, 8.15: SSTI due to Superficial and Subcutaneous fungal infections, Cutaneous and mucosal Candidiasis	Batch -1 (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case V (PERFORM)	PA32.2 Describe the etiology, cause, iodine dependency, pathogenesis, manifestations, laboratory and imaging features and course of thyrotoxicosis	Batch -1 (Patho) PA 19.1 causes and differentiating features of lymphadenopathy SGD	

	various nutrients and special nutritional requirements according to age, sex, activity, physiological conditions	Batch 2 – (Patho) PA 19.3 describe features of tuberculous lymphadenitis in a gross and microscopic specimen DOAP	Batch 2 – (Micro) MI 4.3, 8.15: Anthrax, Leprosy, Pseudomonas, Melioidosis, Actinomycetes, Nocardia MI 1.2: Gram staining-5	PH 1.36 Describe the MOA doses and indications of anti thyroid drugs	Batch 2 – (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case V (PERFORM)	
--	--	---	---	---	---	--

Time	16.8.2021	17.8.2021	18.8.2021	19.8.2021	20.8.2021	21.8.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM8.3 Enumerate and describe disease specific National Health Programs including their prevention and treatment of a case (Malaria)	Patho PA 21.1 Describe normal hemostasis SDL	Pharma PH 1.19 Anti epileptic drugs II	Holiday	Clinics Lecture SURGERY SU 12.1 Enumerate the causes and consequences of malnutrition in the surgical patient SU 12.2 Describe and discuss the methods of estimation and replacement of the fluid and electrolyte requirements in the surgical patient SU 12.3 Discuss the nutritional requirements of surgical patients, the methods of providing nutritional support and their complications	MI 5.2 Viral agents of encephalitis-2: Arboviral encephalitis (JE and West Nile), Nipah virus infection, Slow viral infections

9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting		Clinical Posting	AETCOM (9-11) Module 2.7: Bioethics continued: Case studies on autonomy and decision making Anchoring lecture - 1 hour iv. Discussion and closure of case - 1 hour
						Pharma (11pm -12pm) PH 1.19 Anti Depressants
12 PM-1 PM	Pharma PH 1.19 Anti epileptic drugs I	MI 5.1 Agents of pyogenic meningitis	Patho PA21.2, pathogenesis and pathology ITP and haemophilia's SGD PE 29.6, PE 29.7		Patho PA 21.4 disseminated intravascular coagulation, laboratory findings and diagnosis SGD	MI 5.2 Viral agents of encephalitis-1: Rabies and HSV encephalitis
2PM – 4PM	FMT PRACTICAL - BATCH 1 FM 14.4 AGE ESTIMATION FROM X-RAY (SHOULDER / ELBOW / WRIST) Batch 2 Food items (Fish, egg, meat, milk, fruits) CM 5.1 Describe the common sources of various nutrients and special nutritional requirements according to age, sex, activity, physiological conditions	Batch -1 (Micro) MI 5.1: Agents of aseptic meningitis-1 MI 5.3, 8.15: Agents of pyogenic meningitis	Batch -1 (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case VI (DOAP)		Batch -1 (Patho) PA 19.3 describe features of tuberculous lymphadenitis in a gross and microscopic specimen DOAP	
		Batch 2 – (Patho) PA 19.5 features of Hodgkin's lymphoma in gross and microscopic specimen PA 19.7 gross specimen of an enlarged spleen DOAP	Batch 2 – (Micro) MI 4.1, 4.3, 8.15: Staphylococcal, Streptococcal and Anaerobic infections MI 4.3, 8.15: SSTI due to Superficial and Subcutaneous fungal infections,	Batch 2 – (Pharma) PH 3.5 Prepare and explain a list of P-drugs for a given case VI (DOAP)		

			Cutaneous and mucosal Candidiasis			
--	--	--	-----------------------------------	--	--	--

Time	23.8.2021	24.8.2021	25.8.2021	26.8.2021	27.8.2021	28.8.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.4 MEDICO-LEGAL ASPECTS OF INJURIES - I	Patho PA 21.5 Define and describe disseminated intravascular coagulation and diagnosis of Vitamin K deficiency SGD PE 12.13 PE 12.14	Pharma PH 1.19 drugs on Schizophrenia	Clinics Lecture OBGY OG7.1 Describe and discuss the changes in the genital tract, cardiovascular system, respiratory, haematology, renal and gastrointestinal system in pregnancy. (part 1)	Clinics Lecture SURGERY SU 13.1 Describe the immunological basis of organ transplantation SU 13.2 Discuss the Principles of immunosuppressive therapy. Enumerate Indications, describe surgical principles, management of organ transplantation SU 13.3 Discuss the legal and ethical issues concerning organ donation	MI 4.1,1.1 Tetanus, botulism Neurocysticercosis
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.8: What does it mean to be family member of a sick patient? Hospital visit & interviews - 2 hours
						Pharma (11pm -12pm) PH 1.19 Opioid drugs I

12 PM-1 PM	Pharma PH 1.19 DRugs used for Bipolar Disease	MI 5.2: Viral agents of encephalitis-2	Patho PA 22.1 Classify and describe blood group systems (ABO and RH) FM 14.8 DOAP	MI 5.2: Parasites causing encephalitis	Patho PA22.4 Enumerate blood components and describe their clinical uses SU3.1 OG10.2, IM 9.18, IM 15.12 AS 9.4	Sports
2PM – 4PM	FMT PRACTICAL - BATCH 2 FM 14.4 AGE ESTIMATION FROM X-RAY (SHOULDER / ELBOW / WRIST) CM practical batch 1 Food items (Fish,egg,meat,milk) CM 5.1 Describe the common sources of various nutrients and special nutritional requirements according to age, sex, activity, physiological conditions	Batch -1 (Micro) MI 5.1: Agents of aseptic meningitis-2 MI 5.2, 8.15: Aseptic meningitis	Batch -1 (Pharma) PH 3.4 Recognize and report an adverse drug reaction I	PA32.3 Describe the etiology, pathogenesis, manifestations, laboratory and imaging features and course of thyrotoxicosis/hypothyroidism IM22.2 IM 12.1, IM 12.2 PH 1.36 Anti Thyroid drugs	Batch -1 (Patho)PA 19.5 features of Hodgkin's lymphoma in gross and microscopic specimen PA 19.7 gross specimen of an enlarged spleen DOAP Batch 2 – (Pharma) PH 3.4 Recognize and report an adverse drug reaction I	

Time	30.8.2021	31.8.2021	1.9.2021	2.9.2021	3.9.2021	4.9.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday

8 AM-9 AM	CM8.1 Describe and discuss the epidemiological and control measures including the use of essential laboratory tests at the primary care level for communicable diseases (Leprosy)	Patho PA22.5 Enumerate and describe infections transmitted by blood transfusion SGD	Pharma PH 1.34 Anti emetics and Purgatives	Clinics Lecture MEDICINE IM9.17 Describe the indications for blood transfusion and the appropriate use of blood components IM9.18 Describe the precautions required necessary when performing a blood transfusion	Clinics Lecture OBGY OG7.1 Describe and discuss the changes in the genital tract, cardiovascular system, respiratory, haematology, renal and gastrointestinal system in pregnancy. (part2)	MI 6.1: Viral URTI-2, Fungal URTI:
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.8: What does it mean to be family member of a sick patient? Large Group Discussions with patients' relatives - 1 hour
						Pharma (11pm -12pm) PH 1.36 Diabetes Mellitus I
12 PM-1 PM	Pharma PH 1.19 Opioid drugs II	MI 6.1 Normal commensals and defense mechanisms Infective syndrome of respiratory system	Patho PA 22.6 Describe transfusion reactions and enumerate the steps in the investigation of a transfusion reaction SDL	MI 6.1 Viral URTI-1	Patho PA 22.7 Enumerate the indications and describe the principles and procedure of autologous transfusion	SDL Pharma 6 PH 1.23 Describe the process of drug de-addiction
2PM – 4PM	FMT PRACTICAL - BATCH 1 FM 14.4 AGE ESTIMATION FROM X-RAY (PELVIS) CM practical Batch 2	Batch -1 (Micro) MI 6.2: URTI Throat swab Gram staining-1,2,3 and certification	Batch -1 (Pharma) PH 3.4 Recognize and report an adverse drug reaction II	PA24.2 Describe the etiology, pathogenesis, pathology, microbiology,	Batch -1 (Patho) PA 20.1 Describe the features of plasma cell myeloma DOAP	

	Drugs leprosy, malaria	Batch 2 – (Patho) PA 23.2 abnormal urinary findings in disease states, common urinary abnormalities in a clinical specimen PE 21.11 DOAP	Batch 2 – (Micro) MI 5.1: Agents of aseptic meningitis-2 MI 5.2, 8.15: Aseptic meningitis	clinical and microscopic features of peptic ulcer disease IM15.1, MI 3.6 PH 1.34 Drugs used in Peptic Ulcer disease	Batch 2 – (Pharma) PH 3.4 Recognize and report an adverse drug reaction II	
--	------------------------	---	---	--	--	--

Time	6.9.2021	7.9.2021	8.9.2021	9.9.2021	10.9.2021	11.9.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FM 3.4 MEDICO-LEGAL ASPECTS OF INJURIES - II	Patho PA 23.2 Describe abnormal findings in body fluids in various disease states IM17.7, IM 17.9, MI5.1	Pharma PH 1.41 Drugs used in infertility/erectile dysfunction	Clinics Lecture MEDICINE IM11.1 Define and classify diabetes IM11.4 Describe and discuss the genetic background and the influence of the environment on diabetes	Clinics Lecture OBYG OG7.1 Describe and discuss the changes in the genital tract, cardiovascular system, respiratory, haematology, renal and gastrointestinal system in pregnancy (part 3)	MI 6.1: Tuberculosis & NTM Integrated with Patho, Medicine
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.8: What does it mean to be family member of a sick patient? SDL-2hr
						Pharma (11pm -12pm) PH 1.40 , Tocolytics (SGD 8)

12 PM-1 PM	Pharma PH 1.36 Diabetes Mellitus II	MI 6.1: Agents of typical pneumonia	Path PA 22.2(Patho)enumerate,demonstrate the steps of compatibility testing PA 16.7Describe the correct technique to perform a cross match SGD o IM15.13	MI 6.1: Tuberculosis & NTM Integrated with Patho, Medicine	PA24.1 Describe the etiology, pathogenesis, pathology and clinical features of oral cancers DE 4.1. DE 4.2, DE 4.3 SGD	SDL Patho PA 21.3 Differentiate platelet from clotting disorders based on the clinical and hematologic features
2PM – 4PM	FMT PRACTICAL - BATCH 2 FM 14.4 AGE ESTIMATION FROM X-RAY (PELVIS) CM practical batch 1 drugs leprosy malaria	Batch -1 (Micro) MI 6.3: Sputum Gram staining-1,2,3 and certification	Batch -1 (Pharma) PH 3.4 Recognize and report an adverse drug reaction III	PA24.3 Describe and identify the microscopic features of peptic ulcer IM 15.2, IM 15.3, IM 15.9, IM 15.11 PH 1.34 Describe the MOA doses of drugs in GERD	Batch -1 (Patho) PA 23.2 abnormal urinary findings in disease states,common urinary abnormalities in a clinical specimen PE 21.11 DOAP	
		Batch 2 – PA 23.3Describe and interpret the abnormalities in semen analysis, thyroid function tests, renal function tests ,liver function tests DOAP	Batch 2 – (Micro) Batch -1 (Micro) MI 6.2: URTI Throat swab Gram staining-1,2,3 and certification			

Time	13.9.2021	14.9.2021	15.9.2021	16.9.2021	17.9.2021	18.9.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday

8 AM-9 AM	CM Leprosy national health programe 8.3 Enumerate and describe disease specific National Health Programs including their prevention and treatment of a case (Leprosy)	PA24.5 pathogenesis and pathologic features of Tuberculosis of the intestine PA24.6 pathogenesis and pathologic and distinguishing features of Inflammatory bowel disease IM 16.15	Pharma PH 1.37 Describe the MOA types and indications of drugs (ant. pituitary hormones)	Clinics Lecture MEDICINE IM11.2 Describe and discuss the epidemiology and pathogenesis and risk factors and clinical evolution of type 1 diabetes	Clinics Lecture OBGY OG8.1 Enumerate, describe and discuss the objectives of antenatal care, assessment of period of gestation; screening for high-risk factors. (part1)	MI 7.3: Normal commensals of genitourinary tract Urinary tract infections
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Module 2.8: What does it mean to be family member of a sick patient? Discussion and closure - 1 hour
						Pharma (11pm -12pm) PH 1.38 Describe the MOA,types and doses of Corticosteroids
12 PM-1 PM	Pharma Ph 1.38 Evaluate the indications, C/I and S/E of corticosteroids	MI 6.1: Agents of atypical pneumonia(Bacterial)	PA24.7 Describe the etiology, pathogenesis, pathology and distinguishing features of carcinoma of the colon PA 24.4 carcinoma stomach	MI 6.1: Viral agents of LRTI	PA29.1 Classify and pathogenesis of testicular tumors PA 29.2carcinoma of the penis	SDL Micro MI 6.1 Bacterial URTI
2PM – 4PM	FSM/CM/SDL Batch 2:	Batch -1 (Micro) MI 6.3, 1.2: Laboratory diagnosis of tuberculosis and Acid fast staining-5	Batch -1 (Pharma) PH 3.4 Recognize and report an adverse drug reaction IV	PA24.4 Describe and etiology and pathogenesis and pathologic features of carcinoma of the stomach	Batch -1 (Patho) PA 23.3Describe and interpret the abnormalities in semen analysis, thyroid function tests, renal function tests ,liver function tests	

	CM practical Drugs ARI , Diarrhoea	MI 6.3: Sputum Acid fast staining and certification			DOAP	
		Batch 2 – (Patho) PA24.5,24.6,24.7 DOAP	Batch 2 – (Micro) MI 6.3: Sputum Gram staining-1,2,3 and certification		Batch 2 – (Pharma) PH 3.4 Recognize and report an adverse drug reaction IV	

Time	20.9.2021	21.9.2021	22.9.2021	23.9.2021	24.9.2021	25.9.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FSM	PA29.3 AND PA29.5 benign prostatic hyperplasia SDL	Pharma Ph 1.39 Female gonadal hormones Drugs used in infertility	Clinics Lecture MEDICINE IM11.3 Describe and discuss the epidemiology and pathogenesis and risk factors economic impact and clinical evolution of type 2 diabetes	Clinics Lecture OBYG OG8.1 Enumerate, describe and discuss the objectives of antenatal care, assessment of period of gestation; screening for high-risk factors. (part 2)	MicAgents of vaginal drge Lectureischa
9 AM- 12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	AETCOM (9-11) Pharma (11pm -12pm) Ph 1.39 Drugs used in contraception

12 PM-1 PM	Pharma PH 1.36 Drugs for Osteoporosis	MI 7.1, 7.2: Sexually transmitted infections	PA26.1 Define and describe the etiology, types, pathogenesis, stages, morphology and complications of pneumonia PA26.2 lung abscess	MI 7.2: Agents of genital ulcers-1- Syphilis	PA26.5 Occupational lung disease PA26.6, PA 26.7 tumors of the lung and pleura, mesothelioma	Sports
2PM – 4PM	FSM/CM/SDL Batch 1: CM practical Drugs ARI, Diarrhoea	Batch -1 (Micro) MI 6.1, Fungal agents, Parasitic agents MI 6.3 LRTI Batch 2 – (Patho) PA24.5,24.6,24.7 DOAP	Batch -1 (Pharma) PH 3.6, PH 3.7 List of essential medicines/ optimized interaction with PR for drug information Batch -1 (Micro) MI 6.3, 1.2: Laboratory diagnosis of tuberculosis and Acid fast staining-5 MI 6.3: Sputum Acid fast staining and certification	PA 29.4 Describe the pathogenesis, pathology, hormonal dependency presenting and distinguishing features, diagnostic tests, progression and spread of carcinoma of the prostate	Batch -1 (Patho) PA24.5,24.6,24.7 DOAP Batch 2 – (Pharma) PH 3.6, PH 3.7 List of essential medicines/ optimized interaction with PR for drug information	

Time	27.9.2021	28.9.2021	29.9.2021	30.9.2021	1.10.2021	2.10.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM						

9 AM-12 PM	<h1>Internal assessment</h1>	
12 PM-1 PM		
2PM – 4PM		

Time	4.10.2021	4.10.2021	6.10.2021	7.10.2021	8.10.2021	9.10.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	<h1>Internal assessment</h1>					
9 AM-12 PM						

	Internal assessment		
12 PM-1 PM			
2PM – 4PM			

Time	11.10.2021	12.10.2021	13.10.2021 HOLIDAY	14.10.2021	15.10.2021	16.10.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM 8.1 Describe and discuss the epidemiological and control measures including the use of essential laboratory tests at the primary care level for communicable diseases(ARI)	PA27.1 arteriosclerosis PA 27.2 aneurysms SGD	HOLIDAY	Clinics Lecture MEDICINE IM11.5 Describe and discuss the pathogenesis and temporal evolution of microvascular and macrovascular complications of diabetes	HOLIDAY	MI 1.6: Antimicrobial stewardship
9 AM-12 PM	Clinical Posting	Clinical Posting		Clinical Posting		PA27.5 Describe the epidemiology, risk factors, etiology,

						pathophysiology, pathology, presentations, gross and microscopic features, diagnostic tests and complications of IHD SGD
						Pharma (11pm -12pm) 1.43 Discuss the use of antimicrobials
12 PM-1 PM	Pharma PH 1.42 Describe Principles of Antimicrobial chemotherapy	MI 8.5, MI 8.6: Hospital acquired infections		MI 8.8: Environmental surveillance		SDL Pharma 7 PH 1.58 Describe drugs used in skin disorders
2PM – 4PM	FSM/CM/SDL CM batch 1 SDL; Growth chart	Batch -1 (Micro) MI 7.3: SGD, Agents of UTI Practical on UTI Batch 2 – (Patho) PA26.3 ,pathogenesis, stages, morphology and complications and evaluation of Obstructive airway disease (OAD) and bronchiectasis SGD		PA27.4 Define and describe the etiology, types, pathogenesis, stages, morphology microscopic appearance and complications of tuberculosis PH 1.44 Pharmacotherapy for tuberculosis		

Time	18.10.2021	19.10.2021 HOLIDAY	20.10.2021	21.10.2021	22.10.2021	23.10.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday

8 AM-9 AM	FSM	HOLIDAY	Pharma PH 1.43 Describe the MOA, doses, indications, S/E of Cephalosporins	Clinics Lecture MEDICINE IM11.6 Describe and discuss the pathogenesis and precipitating factors, recognition and management of diabetic emergencies	Clinics Lecture SURGERY SU 4.2 Describe Surgical approaches, incisions and the use of appropriate instruments in Surgery in general SU 4.3 Describe the materials and methods used for surgical wound closure and anastomosis [sutures, knots and needles]	MI 1.1: Infective syndrnes of ear, nose and oral cavity
9 AM-12 PM	Clinical Posting		Clinical Posting	Clinical Posting	Clinical Posting	Patho PA27.10 syphilis on the cardiovascular system PA 27.9 Cardiomyopathies SGD
						Pharma (11pm -12pm) PH 1.43 Describe the MOA, doses, indications, S/E of Monobactams
12 PM-1 PM	Pharma PH1.43 Describe the MOA, doses, indications, S/E of beta lactams		PA27.6 infective endocarditis PA 27.7 pericardial effusion SGD	MI 1.1: Infective syndrnes of eye	PA 28.2 renal failure PA28.4 chronic renal failure SGD	SDL Patho PA28.1 Describe the normal histology of the kidney
2PM – 4PM	FSM/CM/SDL CM SDL Batch 2 Growth chart		Batch -1 (Pharma) PH 5.1, 5.2 Communicate with the patient with empathy and ethics , optimal use of drug therapy/devices	PA27.4 Describe the etiology, pathophysiology, pathology, gross and microscopic features, criteria	Batch 1 PA26.3 pathogenesis, evaluation of Obstructive airway disease (OAD) and bronchiectasis SGD	

			Batch -1 (Micro) MI 6.1, Fungal agents, Parasitic agents MI 6.3 LRTI	and complications of rheumatic fever PH 1.43 Prophylaxis of rheumatic fever	Batch 2 – (Pharma) PH 5.1,5.2 Communicate with the patient with empathy and ethics of drug use , optimal use of drug therapy/devices	
--	--	--	---	---	--	--

Time	25.10.2021	26.10.2021	27.10.2021	28.10.2021	29.10.2021	30.10.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM Diarrhoea (IMNCI)	PA28.6,PA28.7 IgA nephropathy , glomerular manifestation of systemic disease SGD	Pharma PH 1.43 Describe the MOA, doses, indications, S/E of Aminoglycosides II	Clinics Lecture MEDICINE IM12.1 Describe the epidemiology and pathogenesis of hypothyroidism and hyperthyroidism including the influence of iodine deficiency and autoimmunity in the pathogenesis of thyroid disease	Clinics Lecture SURGERY SU 14.1 Describe Aseptic techniques, sterilization and disinfection	MI 8.3: Organisms of oncogenic potential

9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	PA28.8 diseases affecting the tubular interstitium PA 28.9 acute tubular necrosis SGD
						Pharma (11pm -12pm) PH1.43 Describe the MOA, doses, indications, S/E of Sulfonamides, tetracyclines, Cotrimoxazole
12 PM-1 PM	Pharma PH 1.43 Describe the MOA, doses, indications, S/E of Aminoglycosides I	MI 8.1: Zoonotic infections Congenital infections	PA28.12 cystic disease of the kidney SGD	MI 8.2: Opportunistic infections Transplant infections	PA28.14 renal tumours SGD	Sports/SDL
2PM – 4PM	FSM/CM/SDL	Batch -1 (Micro) MI 1.2: Stool microscopy-5	Batch -1 (Pharma) PH 5.3, 5.4 Motivate patients with chronic disease to adhere to the prescribed management, cost management and compliance	PA 28.13 renal stone disease , obstructive uropathy	Batch -1 (Patho) PA27.3 Describe the etiology, types, stages pathophysiology, pathology and complications of heart failure SGD	
	CM SDL 2	Batch 2 – (Patho) PA27.3 Describe the etiology, types, stages pathophysiology, pathology and complications of heart failure SGD	Batch 2 – (Micro) Batch -1 (Micro) MI 7.3: SGD, Agents of UTI Practical on UTI		Batch 2 – (Pharma) PH 5.3, 5.4 Motivate patients with chronic disease to adhere to the prescribed management, cost management and compliance	

Time	1.11.2021	2.11.2021	3.11.2021	4.11.2021	5.11.2021	6.11.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FSM	PA28.11 vascular disease of the kidney SGD	Pharma PH1.43 Describe the MOA, doses, indications, S/E of Fluroquinolones, misc	HOLIDAY	Clinics Lecture SURGERY SU 15.1 Describe classification of hospital waste and appropriate methods of disposal	MI 1.1: Vector-borne infections Laboratory acquired infections
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting		Clinical Posting	PA28.15 thrombotic angiopathies SGD
						Pharma (11pm -12pm) PH 1.44 Describe the MOA, doses, S/E of antitubercular drugs
12 PM-1 PM	Pharma PH1.43 Describe the MOA, doses, indications, S/E of Macrolides and lincosamides	MI 8.4: Emerging and Re-emerging Infections Microbial agents of Bioterrorism	PA30.1 Describe the epidemiology, pathogenesis, etiology, pathology, screening, diagnosis and progression of carcinoma of the cervix SGD		PA30.2 carcinoma endometrium PA 30.3 leiomyoma leiomyosarcoma SGD	Clinics Lecture SURGERY SU 18.1 Describe the pathogenesis, clinical features and management of various cutaneous and submucous infections

2PM – 4PM	FSM/CM/SDL	Batch -1 (Micro) MI 7.1, 7.2: Practical on STI	Batch -1 (Pharma) PH 5.5, 5.6 Educate patients regarding drug dependence and OTC drugs		Batch -1 (Patho) PA27.8 Interpret abnormalities in cardiac function testing in acute coronary syndromes DOAP	
		Batch 2 – (Patho) PA27.8 Interpret abnormalities in cardiac function testing in acute coronary syndromes DOAP	Batch 2 – (Micro) MI 1.2: Stool microscopy-5		Batch 2 – (Pharma) PH 5.5, 5.6 Educate patients regarding drug dependence and OTC drugs	

Time	8.11.2021	9.11.2021	10.11.2021	11.11.2021	12.11.2021	13.11.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FSM	PA 30.5 gestational trophoblastic neoplasms SGD	Pharma PH1.55 Describe the MOA, doses, S/E of Leprosy drugs	Clinics Lecture OBGY OG9.4 Discuss the clinical features, laboratory investigations, ultrasonography, differential diagnosis, principles of management and follow up of gestational trophoblastic neoplasms	Clinics Lecture SURGERY SU 16.1 Minimally invasive General Surgery. Describe indications, advantages and disadvantages of Minimally Invasive General Surgery	MI 8.16: National health programs Integrated with CM
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	PA 30.6 cervicitis PA 30.7 endometriosis SGD

						Pharma (11pm -12pm) PH 1.47 Describe the MOA, doses, S/E of drugs used in malaria and kala azar
12 PM-1 PM	Pharma PH 1.45, PH 1.46 Describe the MOA, doses, S/E of XDR and MDR TB	MI 8.13: Choose appropriate laboratory test in diagnosis of infectious disease (Rational use of microbiological investigations)	PA 30.8 adenomyosis PA 30.9 endometrial hyperplasia SGD	MI 8.16: National health programs Integrated with CM	PA 31.2, PA 31.3 carcinoma breast SGD	SDL Pharma 8 PH 1.63 Discuss pediatric and geriatric pharmacology
2PM – 4PM	FSM/CM/SDL	Batch -1 (Micro) MI 8.11: Demonstrate respect for patient samples sent for lab investigations	Batch -1 (Pharma) PH 5.7 Demonstrate an understanding of legal and ethical aspects of prescribing drugs	PA28.3 Define and describe the etiology, precipitating factors, pathogenesis, pathology, laboratory urinary findings, progression and complications of acute renal failure	Batch -1 (Patho) PA 31.1 benign breast disease PA 31.4 gynaecomatia SGD	
		Batch 2 – (Patho) PA 31.1 benign breast disease PA 31.4 gynaecomatia SGD	Batch 2 – (Micro) MI 7.1, 7.2: Practical on STI		Batch 2 – (Pharma) PH 5.7 Demonstrate an understanding of legal and ethical aspects of prescribing drugs	

Time	15.11.2021	16.11.2021	17.11.2021	18.11.2021	19.11.2021	20.11.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM CM 8.1: Describe and discuss the epidemiological and control measures including the use of essential laboratory tests at the primary care level for communicable diseases (Diarrhoea)	Patho PA 32.5 hyperparathyroidism SGD	Pharma PH 1.48 Describe the MOA, doses, S/E of drugs used in UTI, STD (SGD 9)	Clinics Lecture OBGY OG10.2 Enumerate the indications and describe the appropriate use of blood and blood products, their complications and management.	HOLIDAY	Micro Lecture Revision
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting		PA 32.6 metastasis of pancreatic cancer SGD
						Pharma (11pm -12pm) PH 1.48 Describe the MOA, doses, S/E of drugs used in HIV
12 PM-1 PM	Pharma PH 1.48 Describe the MOA, doses, S/E of drugs used in HIV	Micro Lecture Revision	PA 32.7 adrenal insufficiency SGD	Micro Lecture Revision		SDLPatho PA 32.8 cushing's syndrome SGD

2PM – 4PM	FSM/CM/SDL	Batch -1 (Micro) MI 8.12 Confidentiality pertaining to patient's identity in lab result	Batch -1 (Pharma) PH 3.8 communicate effectively with patients on proper use of medication	PA28.5 Define and classify glomerular diseases. Enumerate and describe the etiology, pathogenesis, mechanisms of glomerular injury, pathology, distinguishing features and clinical manifestations of glomerulonephritis		
		Batch 2 – (Patho) PA 32.9 adrenal neoplasm SGD	Batch 2 – (Micro) MI 8.11: Demonstrate respect for patient samples sent for lab investigations			

Time	22.11.2021	23.11.2021	24.11.2021	25.11.2021	26.11.2021	27.11.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FSM	PA 33.1 osteomyelitis SGD	Pharma PH 1.47 Drugs for amoebiasis and antidiarrheal (SGD 11)	Clinics Lecture OBGY OG8.8 Enumerate the indications and describe the investigations including the use of ultrasound in the initial assessment and monitoring in pregnancy	Clinics Lecture SURGERY SU 17.3 Describe the Principles in management of mass casualties	Micro Lecture Revision
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Patho PA 33.2 bone tumours SGD
						Pharma (11pm -12pm)

						PH 1.55 Drugs for intestinal helminthiasis and filariasis(GSD 12)
12 PM-1 PM	Pharma PH1.43 Drugs used for fungal infection (SGD 10)	Micro Lecture Revision	PA 33.3 soft tissue tumours SGD	Micro Lecture Revision	PA 33.4 Paget's disease of bone SGD	Clinical lecture SURGERY SU 18.2 Classify skin tumours Differentiate different skin tumours and discuss their management
2PM – 4PM	FSM/CM/SDL	Batch -1 (Micro) MI 8.14 Demonstrate confidentiality pertaining to patient's identity in lab result	Batch -1 (Pharma) PH 3.8 communicate effectively with patients on proper use of medication	PA28.10 pathogenesis, pathology, laboratory Human Anatomy findings, distinguishing features progression and complications of acute and chronic pyelonephritis and reflux nephropathy	Batch -1 (Patho) PA 32.9 adrenal neoplasm SGD	
		Batch 2 – (Patho) PA 33.5 rheumatoid arthritis SGD	Batch 2 – (Micro) MI 8.12 Confidentiality pertaining to patient's identity in lab result		Batch 2 – (Pharma) PH 3.8 communicate effectively with patients on proper use of medication	

Time	29.11.2021	30.11.2021	1.12.2021	2.12.2021	3.12.2021	4.12.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM 8.3 Enumerate and describe disease specific National Health Programs including their prevention and treatment of a case (IMNCI-Diarrhoea)	Patho PA34.1 squamous cell carcinoma skin SGD	Pharma PH 1.49 Drugs used in Anticancer therapy (SGD 13)	Clinics Lecture MEDICINE IM12.2 Describe and discuss the genetic basis of some forms of thyroid dysfunction	Clinics Lecture OBGY OG9.1 Classify, define and discusses the aetiology and management of abortions including threatened, incomplete, inevitable, missed and septic (part 1)	Micro Lecture Revision
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Patho PA 34.2 basal cell carcinoma skin SGD
						Pharma (11pm -12pm) PH 1.54 Describe the vaccines and their uses
12 PM-1 PM	Pharma PH 1.49 Principles of Anticancer therapy	Micro Lecture Revision	Patho PA 34.3 melanoma skin SGD	Micro Lecture Revision	Patho PA 34.3 melanoma skin contd SGD	Clinical lecture OBGY OG9.1 Classify, define and discusses the aetiology and management of abortions including threatened, incomplete, inevitable, missed and septic. (part2)

2PM – 4PM	FSM/CM/SDL	Batch -1 (Micro)	Batch -1 (Pharma) PH 3.2 Perform and interpret critical audit of prescription (DOAP)	PA28.16 Describe the etiology, genetics, pathogenesis, pathology, presenting features and progression of urothelial tumors	Batch -1 (Patho)PA 33.5 rheumatoid arthritis SGD	
		Batch 2 – (Patho) PA 33.5 rheumatoid arthritis contdSGD	Batch -2 (Micro) MI 8.14: Demonstrate confidentiality pertaining to patient's identity in lab result		Batch 2 – (Pharma) PH 3.2 Perform and interpret critical audit of prescription (DOAP)	

Time	6.12.2021	7.12.2021	8.12.2021	9.12.2021	10.12.2021	11.12.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	FSM	PA 35.1 Describe the etiology, types and pathogenesis, differentiating factors, CSF findings in meningitis SGD	Pharma PH 1.62 Antiseptic disinfectants (SGD 14)	Clinics Lecture MEDICINE IM12.3 Describe and discuss the physiology of the hypothalamopituitary - thyroid axis, principles of thyroid function testing and alterations in physiologic function IM12.4 Describe and	Clinics Lecture OBY OG9.3 Discuss the aetiology, clinical features, differential diagnosis of acute abdomen in early pregnancy (with a focus on ectopic pregnancy) and enumerate the principles of medical and surgical management	Micro Lecture Revision

				discuss the principles of radio iodine uptake in the diagnosis of thyroid disorders		
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	PA 35.1 Describe the etiology, types and pathogenesis, differentiating factors, CSF findings in meningitis SGD
						Pharma (11pm -12pm) PH 1.52 Describe management of common poisoning (SGD 15)
12 PM-1 PM	Pharma PH 1.53 Describe the heavy metal poisoning and chelating agents	Micro Lecture Revision	PA 35.2 Classify and describe the etiology, genetics, pathogenesis, pathology, presentation sequelae and complications of CNS tumors SGD	Micro Lecture Revision	PathoPA36.1 Describe the etiology, genetics, pathogenesis, pathology, presentation, sequelae and complications of retinoblastoma SGD	SDL Pharma 9 PH 3.3 Critically evaluate Package insert
2PM – 4PM	FSM/CM/SDL	Batch -1 (Micro) Revision	Batch -1 (Pharma) PH 3.2 Perform and interpret critical audit of prescription (PERFORM)	PA30.4 Classify and describe the etiology, pathogenesis, pathology, morphology, clinical course, spread and complications of ovarian tumors	Batch -1 (Patho) PA 35.3 Identify the etiology of meningitis based on given CSF parameters DOAP	
		Batch 2 – (Patho) PA 35.3 Identify the etiology of meningitis based on given CSF parameters DOAP	Batch 2 – (Micro) Revision		Batch 2 – (Pharma) PH 3.2 Perform and interpret critical audit of prescription (PERFORM)	

Time	13.12.2021	14.12.2021	15.12.2021	16.12.2021	17.12.2021	18.12.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	CM CM8.4 Describe the principles and enumerate the measures to control a disease epidemic	PA 31.2 carcinoma breast revision SGD	Pharma PH 1.34 Purgatives and laxatives (SGD 17)	Clinics Lecture MEDICINE IM4.1 Describe and discuss the febrile response and the influence of host immune status, risk factors and comorbidities on the febrile response IM4.2 Describe and discuss the influence of special populations on the febrile response including: the elderly, immune suppression, malignancy and neutropenia, HIV and travel	Clinics Lecture OBYG OG9.5 Describe the etiopathology, impact on maternal and fetal health and principles of management of hyperemesis gravidarum	Micro Lecture Revision
9 AM-12 PM	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Patho PA 26.1 pneumonia revision SGD
						Pharma (11pm -12pm)

						PH 1.63 describe drug regulation acts and other legal aspects (SGD 18)
12 PM-1 PM	Pharma PH 1.57 Describe drugs used in ocular diseases (SGD 16)	Micro Lecture Revision	Patho PA28.5 glomerular disease revision SGD	Micro Lecture	Patho PA 24.7 carcinoma colon revision SGD	SDL PA 29.1 Testicular tumours revision SGD
2PM – 4PM	FSM/CM/SDL	Batch -1 (Micro) Revision	Batch -1 (Pharma) PH 3.3 Perform critical evaluation of the drug promotional literature (DOAP)	PA 32.4 Diabetes mellitus	Batch -1 (Patho) PA 30.1 carcinoma cervix SGD	
		Batch 2 – (Patho) PA 30.1 carcinoma cervix revision SGD	Batch 2 – (Micro) Revision		Batch 2 – (Pharma) PH 3.3 Perform critical evaluation of the drug promotional literature (DOAP)	

Time	20.12.2021	21.12.2021	22.12.2021	23.12.2021	24.12.2021	25.12.2021
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	Internal assessment					
9 AM-12 PM						

12 PM- 1 PM		
2PM – 4PM		

Time	27.12.2021	28.12.2021	29.12.2021	30.12.2021	31.12.2021	1.1.2022
	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
8 AM-9 AM	Internal Assessment					
9 AM- 12 PM						

12 PM- 1 PM		
2PM – 4PM		